Quintrio
Home

COMPUTER PERIPHERAL EQUIPMENT, NEC

Ainos, Inc. Common Stock

AIMD

Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.

Last trade $1.23
Day change +$0.09 (+7.89%)
Day range $0.983 – $1.28
Volume 1,015,827
Market cap $10M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$9.94M
Price / earnings
—
Price / book
3.03×
Price / sales
730.7×
EV / sales
1,434.9×
EV / EBITDA
-2.17×

Profitability

Earnings per share
-$1.66
Return on assets
-73.89%
Return on equity
-440.15%
Dividend yield
0%

Liquidity and leverage

Debt / equity
3.35×
Current ratio
0.13×
Quick ratio
0.12×
Cash ratio
0.09×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.49M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AIMD, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$152$161$11.12K$2.17K$4.66K$106.21K$0$0
Cost of revenue$53$763$1.6K$477$937$18.23K-$79$547
Gross profit$99-$602$9.52K$1.69K$3.73K$87.97K$79-$547
Selling, general and administrative$2.55M$593.19K$2.18M$795.25K$1.84M$1.53M$2.31M$1.02M
Research and development$1.85M$1.69M$2.12M$1.99M$1.91M$1.72M$2.33M$2.02M
Total operating expenses$4.4M$2.28M$4.31M$2.79M$3.75M$3.25M$4.63M$3.04M
Operating income-$4.4M-$2.28M-$4.3M-$2.78M-$3.75M-$3.16M-$4.63M-$3.04M
Interest expense-$200.16K-$176.88K-$176.92K-$176.58K-$177.96K-$180.45K-$184.37K-$264.64K
Income before taxes-$4.59M-$2.46M-$4.47M-$2.93M-$4.08M-$3.29M-$4.65M-$3.7M
Income taxes$0$0$800$0$0$0$800$0
Net income-$4.59M-$2.46M-$4.47M-$2.93M-$4.08M-$3.29M-$4.65M-$3.7M
Net income attributable to common shareholders-$4.59M-$2.46M-$4.47M-$2.93M-$4.08M-$3.29M-$4.65M-$3.7M
EBITDA-$3.21M-$1.11M-$3.1M-$1.58M-$2.55M-$1.99M-$3.44M-$1.83M
Basic earnings per share-$0.62-$0.41-$0.85-$0.64-$0.99-$1.04-$1.61-$1.64
Diluted earnings per share-$0.62-$0.41-$0.85-$0.64-$0.99-$1.04-$1.61-$1.64

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Ainos Posts Wider Loss in Fiscal Q2

Biotechnology company Ainos reported its Q2 2025 financial results, marking its first commercial revenue through AI Nose platform partnerships and ongoing VELDONA therapy clinical trials, while experiencing increased operating expenses and cash decline.

Investing.com

Ainos Inc. Faces Nasdaq Delisting Over Share Price Deficiency - Investing.com

Ainos Inc., a pharmaceutical company, has received a notice from Nasdaq indicating that its stock price has been below the minimum required bid price for continued listing. The company has been granted a period of 180 days to regain compliance, but if it fails to do so, it may face delisting procedures.

PennyStocks

What Data Should You Use to Trade Penny Stocks?

Here's what types of data you should use to buy and sell penny stocks The post What Data Should You Use to Trade Penny Stocks? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

PennyStocks

How Elections Impact Penny Stocks

Here's how elections impact penny stocks in 2024 The post How Elections Impact Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Benzinga

Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance. Marvell said fourth-quarter revenue increased 1% year-over-year to $1.427 billion, which beat the consensus estimate of $1.42 billion. The chip designer reported quarterly earnings of 46 cents per share, which was in line with analyst estimates. Marvell sees first-quarter revenue of $1.15 billion, plus or minus 5%, versus estimates of $1.371 billion. The company sees first-quarter adjusted earnings of 23 cents per share, plus or minus 5 cents per share, versus estimates of 40 cents per share. The company authorized a $3 billion buyback. Marvell Technology shares dipped 9.6% to $76.91 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Ainos, Inc. (NASDAQ: AIMD) jumped 140% to $2.6899 after dipping 18% on Thursday. Psyence Biomedical Ltd. (NASDAQ: PBM) shares climbed 139% to $3.0350. Psyence Biomedical recently announced its subsidiary, Psyence Australia, received Human Research Ethics Committee approval to initiate its Phase IIb study. Safe and Green Development Corporation (NASDAQ: SGD) shares jumped 138% to $1.57 after the company announced financing for the Norman Berry Expansion in Atlanta, Georgia. MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) shares climbed 48.5% to $1.36. MIRA Pharmaceuticals, last month, announced a research collaboration with Pharmaseed to research and evaluate Ketamir for patients with major depressive disorder and post-traumatic stress disorder. CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) shares climbed 35.4% to $4.17 after surging over 20% on Thursday. CERo Therapeutics recently announced the publication of preclinical research analyzing CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients. Willdan Group, Inc. (NASDAQ: WLDN) gained 30.4% to $25.89 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance above estimates. Also, the company secured a contract worth approximately $30 million to $50 million over three years. The Joint Corp. (NASDAQ: JYNT) gained 29% to $11.80 following fourth-quarter results. Smith & Wesson Brands, Inc. (NASDAQ: SWBI) jumped 25.8% to $16.91 after the company reported better-than-expected third-quarter financial results. Research Frontiers Incorporated ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 30, 20251-for-5reverse split
Dec 14, 20231-for-5reverse split
Aug 9, 20221-for-15reverse split